1. Home
  2. ANNX vs SSYS Comparison

ANNX vs SSYS Comparison

Compare ANNX & SSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.39

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Logo Stratasys Ltd. (Israel)

SSYS

Stratasys Ltd. (Israel)

HOLD

Current Price

$8.37

Market Cap

719.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
SSYS
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
812.7M
719.7M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
ANNX
SSYS
Price
$5.39
$8.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$16.50
$12.33
AVG Volume (30 Days)
4.4M
818.6K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$4.48
Revenue Next Year
$16,320.74
$3.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.03
$7.34
52 Week High
$7.18
$12.78

Technical Indicators

Market Signals
Indicator
ANNX
SSYS
Relative Strength Index (RSI) 47.18 46.41
Support Level $4.66 $8.12
Resistance Level $5.65 $8.96
Average True Range (ATR) 0.55 0.30
MACD -0.04 0.00
Stochastic Oscillator 28.70 30.85

Price Performance

Historical Comparison
ANNX
SSYS

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.

Share on Social Networks: